InfinixBio

InfinixBio is a privately held, US-based Contract Research Organization (CRO) founded in 2006 (contradicting some data showing 2018) and headquartered in Columbus, Ohio. The company provides end-to-end R&D services to virtual, mid-size, and pharmaceutical clients, covering early drug development, pre-clinical (GLP/non-GLP) studies, and clinical trial support without taking equity or IP ownership. Its business model is built on a collaborative, project-based partnership approach, utilizing a team with deep scientific expertise and regulatory experience to guide clients through key development milestones and regulatory pathways.

Rapid Innovate Model™ - A proprietary, collaborative project management framework integrating dedicated project teams, subject matter experts, and regulatory experience to guide clients from discovery through early-stage clinical trials.

InfinixBio competes in the fragmented but competitive biotech CRO market against large global players (e.g., IQVIA, Charles River Labs), mid-sized full-service CROs, and niche boutique firms. It differentiates through its collaborative Rapid Innovate Model™, cost-effective Midwest operations, and a broad service suite covering early development to Phase 2.